Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Cancer Immunol Immunother. 2018 Aug 22;67(11):1767–1776. doi: 10.1007/s00262-018-2228-7

Fig. 1:

Fig. 1:

CD8 T cell activation in peripheral blood. (a) Scheme shows treatment and blood sampling schedule. (b) Proliferation of CD4 and CD8 T cells (c) Ki-67 and Bcl-2 expression on CD8 T cells prior to treatment and post cycle 1. Numbers represent frequency among total CD8 T cells. (d) Phenotypic analysis of proliferating CD8 T cells on day 21 post treatment initiation. Numbers represent frequency among Ki-67+ CD8 T cells. Contour plots show total CD8 T cells (grey contour plot) and Ki-67+ CD8 T cells (red dots). C: cycle, Pembro: Pembrolizumab, d: days